PD-1 inhibitors, targeting PD-L1, have been found to be more effective and less toxic than CTLA4 inhibitors in melanoma, indicating the importance of the PD-1/PD-L1 pathway in immunotherapy. Here, CTLA4 is linked to melanoma.